Our Company

Our Purpose

We manage the quality and safety of radiotherapy treatment with the goal of improving patient outcomes and reducing the burden of cancer survivorship.

Our Focus

We focus the passion of our people and the commitment of our company on making a positive difference in the lives of cancer patients.

Our Values

As a company and as a team we constantly strive to infuse honesty, empathy, creativity, curiosity and accountability into everything we do.

Our Team

We're a dedicated and passionate team driven by the deeper purpose of our work.

Our organization leverages expert product design informed by extensive academic and clinical experience, and skilled software engineering with significant radiotherapy-specific domain expertise. We benefit from longstanding relationships with corporate and clinical collaborators, supported by a substantial regulatory infrastructure and a robust quality management system. Together, these strengths underpin our proven track record of commercial success in the field.

Corporate Leadership

Andy serves as Chief Executive Officer of Radialogica and has over twenty-five years of executive leadership and private equity investment experience in the healthcare industry. He previously served as President and Chief Executive Officer of CMS, Inc., the radiotherapy treatment planning company, where he led the successful strategic repositioning and operational restructuring of the business and subsequent sale to Elekta AB. Prior to joining CMS he served for twelve years as an executive of Brown Brothers Harriman in its private equity investment group, with primary responsibility for Brown Brothers' healthcare-oriented venture and growth capital investments. Andy is a Phi Beta Kappa and summa cum laude graduate of Bowdoin College and earned his MBA from the Wharton School of the University of Pennsylvania.

Scott serves as Chief Operating Officer of Radialogica with responsibility for research and product development and service delivery. He previously served as Chief of Clinical Development in the Department of Radiation Oncology at the Washington University School of Medicine and Siteman Cancer Center. Prior to joining the faculty at Washington University, he served as Senior Vice President of Clinical Design and Research at CMS, Inc., before which he was a Research Fellow at the Memorial Sloan-Kettering Cancer Center in New York City. Scott’s research interests focus on the application of Bayesian statistics and decision theory to problems in Oncology. He received his Ph.D. from the University of Tennessee and his MBA from the Olin School of Business at Washington University in St. Louis.